MedTrace Logo

Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)

NCT05658913 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-09-05

No results posted yet for this study

Summary

To collect Tau PET/CT imaging in older adults diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) in the Mismatch Prospective Cohort Study (MPC-Tau) study to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide insight into the phenotypic variability of Alzheimer's Disease and other related pathologies.

Conditions

Interventions

DRUG

AV-1451

This is a cross-sectional study using the radiotracer AV-1451 to determine the relationship of tau pathology to other biomarker data of MPC participants.

Sponsors & Collaborators

Principal Investigators

  • David A. Wolk · University of Pennsylvania Department of Neurology at the Perelman School of Medicine

  • Sandhitsu R. Das · University of Pennsylvania Department of Neurology at the Perelman School of Medicine

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-14
Primary Completion
2027-12-31
Completion
2029-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05658913 on ClinicalTrials.gov